{"entity":{"id":"rock425","kind":"drug","name":"Rock425","aka":["CCR4-IL2 IT","CCR4-IL2 bispecific immunotoxin"],"tldr":"Rock425 is an experimental immunotoxin from Rock Immune that carries a disabled diphtheria toxin to malignant T cells. It is being developed for cutaneous T-cell lymphoma and has not yet been tested in people.","summary":"Rock425 (CCR4-IL2 IT) is Rock Immune's lead candidate: a genetically engineered protein containing an anti-human CCR4 scFv and human IL-2 fused to truncated diphtheria toxin, expressed in the company's diphtheria toxin-resistant Pichia pastoris system. Rock Immune reports preclinical efficacy in a mouse model of human cutaneous T-cell lymphoma. No registered trial was found.","status":"preclinical","asOf":"2026-11-04","links":[{"label":"Rock Immune","url":"https://rockimmune.com/"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["ccr4"],"drugs":[],"companies":["rock-immune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"modality":"Recombinant immunotoxin (bispecific fusion protein)","mechanism":"An anti-CCR4 single-chain antibody fragment and human IL-2 fused to a truncated diphtheria toxin, so that the toxin is carried into cells bearing CCR4 or the IL-2 receptor, as described by Rock Immune.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/rock425/","neighbours":{"target":[{"id":"ccr4","kind":"target","name":"CCR4","route":"/targets/ccr4/"}],"company":[{"id":"rock-immune","kind":"company","name":"Rock Immune","route":"/companies/rock-immune/"}]}}